RECEIVED CENTRAL FAX CENTER

JAN 1 0 2008

App. No. 10/526,858 Office Action Dated July 18, 2007

## AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listing of claims in the application. No new matter is added.

## **Listing of Claims:**

- 1-14. (CANCELED)
- 15. (CURRENTLY AMENDED) The method of claim 27, wherein a therapeutically effective amount of [[a]] the compound of the formula (I) wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>5</sup>, R<sup>6</sup>, A, B, G, Q and X are as defined above; or a pharmaceutically acceptable salt thereof is administered simultaneously with the other antitumor agent.
- (CURRENTLY AMENDED) The method of claim 27, wherein a therapeutically 16. effective amount of [[a]] the compound of the formula (I) wherein  $R^+$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^{13}$ , R<sup>1-4</sup>, R<sup>5</sup>, R<sup>6</sup>, A, B, G, Q and X are as defined above, or a pharmaceutically acceptable salt thereof is administered in combination with the other antitumor agent sequentially.

17-26. (CANCELED)

(CURRENTLY AMENDED) A method for treating a patient suffering from at 27. least one malignant tumor selected from the group consisting of blood cancer, leukemia, human colon adenocarcinoma, gastrointestinal cancer, lung cancer, breast cancer, and prostate cancer, the method malignant tumor comprising administering a therapeutically

App. No. 10/526,858
Office Action Dated July 18, 2007

effective amount of the compound of the following formula (I), of at least one compound selected from the group consisting of (E)-4-[2-[N-[(p-

methoxyphenyl]sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine, (E)-4-[2-[2-[N-(2-hydroxyethyl)-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide, and (E)-4-[2-[2-[N-(2-hydroxyethyl)-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide,

methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine or a pharmaceutically acceptable salt thereof in combination with at least one other antitumor agent to the patient in need thereof, wherein the other antitumor agent is selected from the group consisting of cisplatin and carboplatin.[[:]]

wherein-R<sup>+</sup> and R<sup>2</sup> are the same or different and each represents hydrogen, alkyl of 1-6 earbon atoms, acyl of 1-6 carbon atoms, cyano, or COOR (R represents hydrogen or C1-6 alkyl);

App. No. 10/526,858 Office Action Dated July 18, 2007

R<sup>3</sup>, R<sup>4</sup>, R<sup>13</sup> and R<sup>14</sup> are the same or different and each represents hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogenealkoxy of 1-6 carbon atoms, acyloxy of 1-6 carbon atoms, hydroxy, halogen, nitro, cyano, amino, acylomino of 1-6 carbon atoms, aminoalkoxy of 1-6 carbon atoms, or morpholinealkoxy with 1-6 carbon atoms in the alkyl moiety;

R<sup>3</sup>-and R<sup>13</sup>-or R<sup>4</sup>-and R<sup>14</sup>-may independently combine together to form mothylenedioxy;
R<sup>5</sup>-represents (1) hydrogen, (2) alkyl of 1-6 carbon atoms which is optionally substituted by halogen, amino, monoalkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms, morpholino, alkoxy of 1-6 carbon atoms, or hydroxy, (3) alkenyl of 2-6 carbon atoms which is optionally substituted by halogen, (4) alkynyl of 2-6 carbon atoms, or (5) acyl of 1-6 carbon atoms;

R<sup>6</sup> represents (1) aroyl of 7-11 carbon atoms which is optionally substituted by alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, or halogen or (2) arylsulfonyl of 6-10 carbon atoms which is optionally substituted by alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogenealkoxy of 1-6 carbon atoms, hydroxy, nitro, or halogen; and A, B, G, Q and X may be the same or different and each represents N, CH, N+O, or N<sup>1</sup>-(R<sup>3</sup>)E<sup>-</sup>(R<sup>3</sup>-represents alkyl of 1-6 carbon atoms or arylalkyl of 7-14 carbon atoms; E<sup>-</sup> represents a counterion for N<sup>4</sup>);

provided that those wherein A, B, and G concurrently represent N, and those wherein A, B, G, Q, and X concurrently represent CH are excluded; and when any of A, B, G, Q and

App. No. 10/526,858 Office Action Dated July 18, 2007

X represents N · O or N + (R +)E, only either of X or Q on Ring Y and/or only one of A, B and G on Ring Z can represent N · O or N + (R +)E.